Why Is Retacrit So Hard to Find? [Explained for 2026]

If you or someone you care for depends on Retacrit (epoetin alfa-epbx) to manage anemia, you may already know the frustration of calling pharmacy after pharmacy only to hear "we're out of stock." You're not alone — Retacrit has had a bumpy supply history, and even when there isn't a formal national shortage, localized gaps happen. Here's the full picture.

What Is Retacrit and Who Needs It?

Retacrit is a biosimilar to Epogen and Procrit (epoetin alfa), approved by the FDA in May 2018 as the first biosimilar erythropoiesis-stimulating agent (ESA) in the United States. It is manufactured by Hospira, a Pfizer company. Retacrit works by mimicking the natural hormone erythropoietin — telling the bone marrow to produce more red blood cells.

It is FDA-approved to treat four types of anemia:

• Anemia caused by Chronic Kidney Disease (CKD), both in dialysis and non-dialysis patients
• Anemia from zidovudine (AZT) treatment in HIV-positive patients
• Anemia caused by myelosuppressive chemotherapy in cancer patients
• Reduction of red blood cell transfusions in patients undergoing certain elective surgeries

Because of these diverse and often serious use cases, patients who rely on Retacrit cannot simply skip a dose without medical risk.

Retacrit's Shortage History: What Happened?

Retacrit has experienced at least two significant supply disruptions since its U.S. launch:

• 2022 shortage: Pfizer notified payers in late March 2022 that Retacrit would experience a supply disruption beginning in late May 2022, with a targeted return to supply by early Q4 2022. During this period, patients were advised to transition to Epogen or Procrit.
• 2023 shortage: A second supply disruption began around September 2023, prompting some insurers to temporarily suspend Retacrit as their preferred product and revert to Epogen and Procrit as alternatives.

As of mid-2025, Pfizer has reported Retacrit available in multiple strengths. However, the ESA category as a whole has seen ongoing strain, and individual pharmacy stocking of specialty injectables can vary significantly by region and by specific vial strength.

Why Is Retacrit Hard to Find Even When There's No Official Shortage?

Even during periods without a formal FDA shortage listing, Retacrit can be difficult to locate. Here are the main reasons:

1. It's a specialty drug. Retacrit is an injectable biologic that most retail pharmacies don't stock. It's primarily dispensed through specialty pharmacies, hospital outpatient pharmacies, or administered directly in dialysis centers and infusion clinics.
2. Multiple vial strengths complicate supply. Retacrit comes in 2,000, 3,000, 4,000, 10,000, and 40,000 Units/mL single-dose vials, and 20,000 Units/mL multi-dose vials. A pharmacy may stock one strength but not another.
3. Cold chain logistics. As a biologic, Retacrit must be refrigerated (2°C–8°C). Cold chain requirements mean fewer distribution points compared to standard oral medications.
4. Interchangeability restrictions. Retacrit is NOT designated as interchangeable with Epogen or Procrit, meaning pharmacies cannot automatically substitute one for another. Each switch requires prescriber approval, adding delays.
5. Manufacturing complexity. Biologic drugs like Retacrit are made using living cell cultures — a far more complex process than synthesizing a small-molecule drug. Any quality issue at the manufacturing facility can halt production for months.

What's the Difference Between Retacrit, Epogen, and Procrit?

All three contain epoetin alfa and have the same FDA-approved indications and dosing. The key difference is origin:

• Epogen (Amgen) — original brand, widely used in dialysis settings
• Procrit (Janssen) — original brand, widely used in oncology and non-dialysis settings
• Retacrit (Pfizer/Hospira) — biosimilar to both, approved across all the same indications, typically lower cost, but NOT interchangeable without prescriber approval

Unlike a generic pill swap, switching from Retacrit to Epogen or Procrit — or vice versa — requires explicit prescriber authorization. This creates delays when one product is unavailable.

How Can I Tell If My Pharmacy Has Retacrit Right Now?

Because Retacrit is a specialty injectable, traditional pharmacy websites usually don't show real-time stock for it. The most reliable methods are:

1. Call your specialty pharmacy directly and ask if they have your specific strength and vial type in stock.
2. Use medfinder — a service that calls pharmacies near you to check which ones can fill your Retacrit prescription, so you don't have to spend hours on hold.
3. Contact your prescriber's office — dialysis centers and oncology infusion centers often stock Retacrit directly and administer it on-site rather than dispensing through a pharmacy.

What Should I Do If I Can't Find Retacrit?

Never discontinue Retacrit without talking to your prescriber. Here are your options if your current source is out of stock:

• Ask your doctor about switching to Epogen or Procrit temporarily. They have the same active ingredient and indications.
• Ask about Aranesp (darbepoetin alfa) — a longer-acting ESA alternative used for CKD and chemotherapy-induced anemia.
• Try a different specialty pharmacy or infusion center. Retacrit inventory varies by distributor and region.
• Contact Pfizer Oncology Together at 1-877-744-5675 — they may be able to help connect you with a source or patient assistance.

Is Retacrit Currently in Shortage in 2026?

As of mid-2025, ASHP (the American Society of Health-System Pharmacists) confirmed that Pfizer has Retacrit available. There is no active nationwide shortage designation for Retacrit heading into 2026. However, some strengths or vial types may be harder to source regionally, and the ESA category overall has faced intermittent stress. Always verify availability with your specific pharmacy before you run out.

For step-by-step guidance on locating Retacrit near you, see our guide on how to find Retacrit in stock near you.

The Bottom Line

Retacrit is a life-sustaining medication for many patients with CKD, cancer, and HIV-related anemia. Its specialty nature, cold chain requirements, and biosimilar interchangeability restrictions make it uniquely vulnerable to localized supply gaps. If you're struggling to find it, don't wait — act early, talk to your prescriber about backup options, and use tools like medfinder to take the legwork out of pharmacy searches.